Approved for use through 12/31/2008. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/650,608	
Filing Date	28 August 2003	
First Named Inventor	Jean-Paul Cassart	
Title	Tumor Specific Animal Protein	
Art Unit	1642	
Examiner Name	Minh-Tam Davis	
Attorney Docket Number	BC45300-1US	

I hereby revoke all previous powers of attorney given in the abo	ve-identified a	application.		
I hereby appoint:				
Practitioners associated with the Customer Numbers.	23347	•		
Or				
☐ Practitioner(s) named below:				
Name		Registration Number		
·				
As my/our attorney(s) or agent(s) to prosecute the application ic		e, and to transact all business in the		
United States Patent and Trademark Office connected therewith	l .			
Please recognize or change the correspondence address for the		ed application to:		
The address associated with the above-mentioned Customer	r Number:			
Or				
☐ The address associated with Customer Number 23347				
Or				
☐ Firm or Individual Name:		***************************************		
Address:		,		
Address:				
City:	State:	Zip:		
Country:				
Telephone:	Fax:			
I am the:				
☐ Applicant/Inventor: ☐ Assignee or record of the entire interest. See 37 CFR:	2 71			
Assignee or record of the entire interest. See 37 CFR Statement under 37 CFR 3.73(b) is enclosed. (Form P				
Statement under 57 CFR 5.75(b) is enclosed. (Form F	<u>-</u>	signes of Decord		
Signature: 2 All Brents	pheant or As	Date: 6 Mach 2009		
Name: Robert H. Brink		Telephone: 919-483-3323		
Title and Company: Attorney, GlaxoSmithKline Biologicals,	S A	1 telephone. 919-463-3323		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.				
		erest or their representative(s) are required.		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 7/31/2006. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner: GLAXOSMITHKLINE BIOLOGICALS, SA				
Application No./Patent No.: 10/650,608 Filed/Issue Date: 28 August 2003				
Entitled: Tumor Specific Animal Protein				
CLAVOSMITHIZITUE DIOLOCICALS SA a composition states the	at it is.			
GLAXOSMITHKLINE BIOLOGICALS, SA, a corporation, states that 1. the assignee of the entire right, title, and interest; or	at it is:			
2. \square an assignee of less than the entire right, title and interest.				
The extent (by percentage) of its ownership interest is 100% in the	natent application/patent identified above			
by virtue of either;	parent approances parent racinistica accept			
A. [X] An assignment from the inventor(s) of the patent application/	patent identified above. The assignment was			
recorded in the United States Patent and Trademark Office at				
copy thereof is attached.				
OR	•			
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee				
as shown below:				
1. From: To:				
The document was recorded in the United States Patent a				
Reel Frame , c	or for which a copy thereof is attached.			
2. From: To:	1.50.00			
The document was recorded in the United States Patent and Trademark Office at				
Reel , Frame , C	or for which a copy thereof is attached.			
3. From: To: To: The document was recorded in the United States Patent and Trademark Office at				
Reel, Frame, or, Reel, Reel	or for which a copy thereof is attached.			
[X] Copies of assignments or other documents in the chain of title are att				
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO.				
See MPEP 3 02.08]				
500 MI DI 502.00]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
l				
Robert A Brent	6 March 2009 Date			
Signature	Date			
Robert H. Brink	919-483-3323			
Printed or Typed Name	Telephone Number			
Attornay				
Attorney Title				
Time				

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Docket No.: BC45300-1

Inventor 5

Carlota VINALS Y DE BASSOLS

ASSIGNMENT

WHEREAS I/We, Jean-Pol CASSART, Teresa Elisa Virginia CABEZON-SILVA, . Thierry COCHE, Swann Romain Jean-Thomas GAULIS and Carlota VINALS Y DE BASSOLS all of RIXENSART, BELGIUM have made an invention entitled:

TUMOR SPECIFIC ANIMAL PROTEINS

NOW, THEREFORE, in return for valuable consideration paid to me/us by GlaxoSmithKline Biologicals s.a. (formerly known as SmithKline Beecham Biologicals s.a.) of Rue de l'Institut 89, B-1330 Rixensart, Belgium (hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged and intending to be legally bound, I/we do hereby assign unto the said ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention, said executed application, any division, continuation and continuation-in-part of said application and reissue applications, and all Letters Patents of the United States of America to be obtained therefor;

I/we hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts and documents relating to said invention, and said Letters Patent as may be known and accessible to me/us, and to testify as to the same in any interference or litigation related thereto, and to execute further instruments (including divisional, continuation, continuation-in-part or reissue applications, affidavits or other instruments) required to apply for, obtain, maintain and enforce said application and said Letters Patent which may be necessary; this agreement to be binding upon my/our heirs, executors and administrators.

Date: 02/03/04

A STORAGE OF THE STOR		02/03/04
Inventor I	Date:	<u> </u>
Jean-Pol CASSART		
T	Date:	08/03/04
Inventor 2		N
Teresa Elisa Virginia CABEZON-SILVA		
	Date:	04/03/04
Inventor 3		
Thierry COCHE		
_ Sun	Date:	02/03/04
Inventor 4	******	ye
Swann Romain Jean-Thomas GAULIS		



POWER OF ATTORNEY

GlaxoSmithKline Biologicals SA Rue de l'Institut, 89 B-1330 Rixensart Belgique

Tel. +32 (0) 2 656 81 11 Fax. +32 (0) 2 656 80 00 www.qsk-bio.com

BY THIS POWER OF ATTORNEY given this 26th day of May two thousand and eight GLAXOSMITHKLINE BIOLOGICALS SA, a company incorporated in Belgium (Registration No. RPM Nivelles 0440.872.918) and having its registered office at Rue de l'Institut 89 B-1330 Rixensart, Belgium, (hereinafter called "the Company"), HEREBY appoints SHERRY M. KNOWLES, ARTHUR W. R. TYRRELL, MARCUS J. W. DALTON, ROBERT H. BRINK, PETER J. GIDDINGS, EDWARD R. GIMMI, HUGH B. DAWSON, PETER I. DOLTON, WENDY A. FILLER, THEODORE R. FURMAN, CHARLES M. KINZIG, HELEN K. QUILLIN, MARY E. McCARTHY, JEFFREY A. SUTTON, STEPHEN VENETIANER, SUSAN M. WHITE and jointly and severally to be its true and lawful agents and attorneys (hereinafter called "the Attorneys," and each an "Attorney") on behalf and in the name of the Company or otherwise to do, perform, exercise or execute or concur with any other person or persons in doing, performing or exercising in or for any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things in connection with: letters patent, including extensions thereto (including supplementary protection certificates and the like); utility models; copyrights; trademark registrations; trademarks: trade names; trade dress; logos; design rights; designs and all rights analogous thereto and all applications therefor and any other forms whatsoever of intellectual property rights; including know-how, all of which are hereinafter called "Intellectual Property Rights", that is to say:

- In any country or countries or jurisdiction in any part of the world to make application or cause application to be made for the grant or issue or transfer to the Company or registration in its name of Intellectual Property Rights and to take all steps necessary for the same to be prosecuted, maintained, withdrawn, renewed, enforced, defended or extended.
- 2. As the act and deed of the Company to sign, seal, deliver and execute all or any assignments or assurances, licences to the Company of or under any Intellectual Property Rights or the right to and interest in any inventions to be the subject of Intellectual Property Rights for the purpose of fully and effectually vesting and transferring the same in and to the Company.
- 3. As the act and deed of the Company to sign and execute all or any assignments and acceptances of the transfer or assignment of such rights, and also any licences, sub-licences and consents from the Company of or under any Intellectual Property Rights or the right to and interest in any invention to be the subject of Intellectual Property Rights, for the purpose of fully and effectually vesting transferring or granting the same in and to any entity, whether in the United Kingdom or elsewhere, in so far as such

documents can be executed without the Company's seal being affixed thereto. For purposes of this Power of Attorney, the terms "entity" means, and includes, any person, firm or company or group of persons or unincorporated body.

To give undertakings or assurances to third parties and to any Trademark Registry or official intellectual property agency or governmental department or otherwise responsible for the registration or protection of trademarks, trade names, trade dress, logos, design rights or designs for the purpose of best protecting or ensuring the coexistence of the Company's rights to trademarks, trade names, trade dress, logos, design rights or designs.

- To commence, prosecute and defend any proceedings or applications whether judicial or extra judicial relating to Intellectual Property Rights and to maintain, withdraw or settle the same.
- For and in connection with any Intellectual Property Rights to sign, seal, deliver and execute any Power of Attorney or other deed or document authorising any agent, including trademark and patent agents and attorneys, to act on behalf of the Company.
- To apply for the registration, amendment or cancellation of user rights in respect of any trademark or trade name.
- 8. To act in regard to all official communications which may now or hereafter be addressed to the Attorneys relating to Intellectual Property Rights or the renewal thereof in such manner that the Attorneys may be recognised as the authorised agent(s) of the Company in all proceedings in relation thereto.
- 9. For all or any of the purposes contained herein as the act and deed of the Company to sign, seal, deliver, execute and do all such documents, deeds, agreements, instruments and to do such acts as shall be requisite or may be deemed proper for or in relation to the said purposes.

It is hereby agreed that:

- (a) this power of attorney shall remain in force until 30 June 2010 or (in respect of any Attorney) until his or her employment by the GlaxoSmithKline group of companies ceases, or until revocation by the Company, whichever first occurs; and
- (b) in respect of any Attorney this power of attorney shall supersede and revoke with effect from the day and year first before written any power of attorney granted by the Company in favour of that Attorney covering all or some of the authorities herein contained.

AND THE COMPANY HEREBY RATIFIES and confirms and agrees to ratify and confirm all and whatsoever the Attorneys or any person, persons, firm or company appointed by them shall lawfully do or have done by virtue of the authorities herein contained.

AND THE COMPANY HEREBY DECLARES that all instruments executed under and by virtue of this Power can be validly executed without the seal of the Company being affixed.

IN WITNESS whereof this Power of Attorney has been executed by GLAXOSMITHKLINE BIOLOGICALS SA the day and year first before written.

GLAXOSMITHKLINE BIOLOGICALS SA

Jean-Pierre Suin

Director

Denis Dubru Director